-
1 month ago | 
healio.com | Rebecca Forand |Kristen Dowd |Valerie D. Callender |Shawn G. Kwatra
Key takeaways: Diverse patient populations are needed for accurate clinical testing. Four experts discussed the challenges to creating diverse teams and recruiting diverse patients. ORLANDO — Increasing diversity in research, from basic and translational to clinical science, is more important than ever and clinicians need to meet people where they are to do so, according to a panel discussion here. John E.
-
1 month ago | 
ajmc.com | Cameron Santoro |Shawn G. Kwatra
This content was produced independently by The American Journal of Managed Care® (AJMC®) and is not endorsed by the American Academy of Dermatology.
-
1 month ago | 
dermatologytimes.com | Kaitlyn Bader |Shawn G. Kwatra
Author(s):,Shawn Kwatra, MD, FAAD, reviews his late-breaking data presentation at AAD on the first original studies of a topical cream for prurigo nodularis. “This is the first study ever conducted for a topical agent for the treatment of prurigo nodularis. So really opening up avenues for the development and treatment. We'revery excited about this for our patients,” said Shawna Kwatra, MD, FAAD, in an interview at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida.
-
Jan 10, 2025 | 
dermatologytimes.com | Shawn G. Kwatra
OpinionVideoJanuary 10, 2025Author(s):A panelist discusses how this patient's history of chronic kidney disease, diabetes, and psychological stress are significant contributing factors to his prurigo nodularis, necessitating a comprehensive treatment approach that addresses both the underlying conditions and the itch-scratch cycle. Please provide your initial impressions of this case. What factors in this patient’s history may be contributing to his prurigo nodularis?
-
Oct 25, 2024 | 
dermatologytimes.com | Kaitlyn Bader |Shawn G. Kwatra
“One of the main themes of our session was every dermatologist, every physician, every provider who takes care of dermatology patients should be asking their patients about itch,” said Shawn Kwatra, MD, in an interview with Dermatology Times at Fall Clinical 2024.
-
Jul 30, 2024 | 
nature.com | Shawn G. Kwatra
AbstractChronic pruritus of unknown origin (CPUO) is characterized by chronic itch for 6 weeks or greater without an identifiable primary cause. Studies are needed to investigate circulating blood biomarkers to elucidate disease pathogenesis. The objective of this study was to investigate changes in circulating blood metabolites in CPUO patients and to identify potential therapeutic targets.
-
Jul 18, 2024 | 
newsbreak.com | Shawn G. Kwatra
Welcome to NewsBreak, an open platform where diverse perspectives converge. Most of our content comes from established publications and journalists, as well as from our extensive network of tens of thousands of creators who contribute to our platform. We empower individuals to share insightful viewpoints through short posts and comments.
-
Jul 18, 2024 | 
newsbreak.com | Shawn G. Kwatra
Welcome to NewsBreak, an open platform where diverse perspectives converge. Most of our content comes from established publications and journalists, as well as from our extensive network of tens of thousands of creators who contribute to our platform. We empower individuals to share insightful viewpoints through short posts and comments.
-
Jul 18, 2024 | 
hcplive.com | Shawn G. Kwatra
July 18, 2024Shawn Kwatra, MD, discusses the durability of treatments for atopic dermatitis and provides advice for clinicians on improving patients’ quality of life. Video content above is prompted by the following questions:How durable is the impact of AD treatments on patients’ QoL? What advice can you share with clinicians to improve the quality of life of patients with AD? Related Content Related Content
-
Jul 18, 2024 | 
hcplive.com | Shawn G. Kwatra
July 18, 2024An expert on skin conditions provides an overview of TARGET-DERM, a real-world study of patient-reported outcomes in atopic dermatitis. Video content above is prompted by the following questions:Can you discuss recently presented data from TARGET-DERM, a longitudinal, observational study, on the effect of skin severity and itch (both independent and combined) on patients’ QoL (RAD 2024 meeting)? What do these data mean for clinicians? Related Content Related Content
